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ological significance of the Ephs and 
ephrins in insulin secretion in vivo by 
creating and characterizing β cell-
specific inducible knockouts of spe-
cific Ephs and/or ephrins. It is notable 
that EphA5 is localized to the insulin 
secretory granule, an organelle that 
is also associated with ATP-depend-
ent K channels, glucokinase, and the 
insulin receptor (Geng et al., 2003; 
Hribal et al., 2003). Whether the close 
association between these proteins 
is necessary for intracrine regulation 
at the level of the secretory granule is 
worth investigating.
Glucose-stimulated insulin release 
typically occurs in two phases—a 
rapid first phase (2–3 min in the 
mouse and 10 min in humans) after 
glucose stimulation and a pro-
longed second phase that lasts up 
to 30 min. In contrast to many fac-
tors—such as the insulin receptor 
tyrosine kinase—that regulates the 
first phase glucose-induced insu-
lin release (Kulkarni et al., 1999), 
Eph-ephrin signaling predominantly 
affects the second phase of insulin 
release. Another avenue to pursue is 
whether there might be interaction 
between these two RTK systems 
that both regulate β cell function and 
insulin secretion.
Although a part of the mystery 
underlying β cell-to-β cell commu-
nication has been unraveled, the 
relevance of these observations to 
disease needs clarification. Could 
abnormalities in the expression 
of Ephs and ephrins contribute to 
defects in altered insulin secretion 
or maintenance of β cell mass that 
are characteristic of type 2 diabetes 
or other insulin-resistant states? Are 
there polymorphisms in the genes 
that code for Ephs and ephrins that 
are associated with altered glucose 
homeostasis in humans? Further 
integrative studies should help define 
the functions of Ephs and ephrins 
and their role in diabetes and meta-
bolic diseases.
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Although human blood plasma contains molecules that inhibit the activity of HIV-1, their 
identity is largely unknown. Münch et al. (2007) now identify a peptide corresponding to a 
portion of α1-antitrypsin that potently inhibits entry of HIV-1 into host cells by binding to a 
hydrophobic segment of the viral envelope glycoprotein gp41.A number of molecules have been 
discovered that can inhibit the entry 
of HIV-1 and other viruses into cells 
of their host (reviewed in Dimitrov, 
2004; Liu et al., 2007). Perhaps 
the most well-known are the anti-
HIV peptides SJ-2176 (Jiang et al., 
1993) and T20 (Wild et al., 1994) 
derived from the C-terminal heptad 
repeat region of the viral envelope 
glycoprotein gp41. T20 remains the only HIV-1 entry inhibitor approved 
for clinical use by the US Food and 
Drug Administration. The search 
for peptides with similar or greater 
potency and crossreactivity and 
improved pharmacokinetics has yet 
to yield additional peptide-based 
therapeutics of clinical utility. Fol-
lowing the example of T20, research 
has remained largely focused on 
peptides derived from viruses. How-Cell 129ever, human blood plasma contains 
naturally occurring low-molecular-
weight protein inhibitors of HIV-1 
infection. Although the possibility of 
finding inhibitory peptides in human 
blood plasma has long been recog-
nized, until recently the task of iden-
tifying them from a mixture of more 
than one million different peptides 
and small proteins has been daunt-
ing. Now, using a peptide library , April 20, 2007 ©2007 Elsevier Inc. 243
extracted from 10,000 liters of human 
hemofiltrate, Münch et al. (2007) have 
identified a peptide—VIRIP for VIRUS-
INHIBITORY PEPTIDE—that potently 
inhibits HIV-1 entry into cells.
Münch et al. used a straightfor-
ward, systematic, and labor-intensive 
approach to identify VIRIP hidden 
among an enormous number of other 
peptide molecules. They fraction-
ated peptides from hemofiltrate by 
cation-exchange and reverse-phase 
chromatography into 322 fractions 
and identified one that inhibited HIV-1 
activity without cellular toxicity. Fur-
ther analysis of this fraction revealed 
VIRIP, a 20-residue peptide corre-
sponding to the C-proximal region 
of the most abundant circulating ser-
ine protease inhibitor α1-antitrypsin. 
VIRIP inhibited primary isolates 
of HIV-1 from different clades and 
inhibited HIV isolates that use differ-
ent coreceptors for entry. VIRIP also 
inhibited variants of HIV resistant to 
protease and reverse transcriptase 
inhibitors as well variants resistant to 
the fusion inhibitor T20.
The inhibitory activity of VIRIP was 
further improved by a systematic 
analysis of the relationship between 
structure and activity. Residues criti-
cal for its activity were initially identi-
fied, and then a series of more than 
600 chemically synthesized VIRIP 
analogs were analyzed. Several of 
these VIRIP derivatives containing 
intramolecular disulfide bonds and 
other modifications exhibited neutral-
izing activity toward HIV in vitro up to 
two orders of magnitude higher than 
that of VIRIP. Although the neutral-
izing activity of these VIRIP deriva-
tives is comparable to that of T20, 
T20 inhibits cell fusion at significantly 
lower concentrations than these pep-
tides. What causes these differences 
is not clear and may depend on the 
assay used and the isolate tested. 
Cell-to-cell transmission of HIV-1 is 
much more efficient than transmis-
sion by cell-free virus (Dimitrov et 
al., 1993) and could be dominant in 
vivo. In contrast to other inhibitors 
including T20, HIV-1 was not able to 
generate resistant strains to one of 
the most extensively characterized 
VIRIP variants (VIR-576). If replicated 244 Cell 129, April 20, 2007 ©2007 Elsein humans this property alone of VIR-
576 would set it apart from existing 
inhibitors that affect other stages of 
the HIV-1 life cycle.
Remarkably, the target for VIRIP 
turned out to be the fusion peptide 
region of HIV-1 gp41, a glycoprotein 
that forms a trimer with gp120. The 
identification of the hydrophobic 
fusion peptide as the target is surpris-
ing because its role in the fusion cas-
cade leading to virus entry has been 
elusive (Gallo et al., 2003). Moreover, 
raising antibodies against this region 
has proven exceedingly difficult 
(C.C. Broder, personal communica-
tion). According to the “sticky finger” 
model, drawn in many cartoons of 
the HIV-1 fusion reaction, the fusion 
peptide inserts into the target cell fol-
lowing the change of conformation 
of gp120-gp41, called “triggering,” 
that occurs subsequent to binding 
of gp120 to host cell CD4 and core-
ceptors. Yet, if the fusion peptide is 
a target for VIRIP, which binds to the 
aqueous form of the fusion peptide, 
this poses a conundrum. This is due 
to the fact that gp41 may rapidly dip 
its sticky finger into the bilayer once 
the trigger has been pulled. Con-
sequently, the sticky finger should 
avoid interference by VIRIP because 
the bilayer-inserted fusion peptide 
will no longer be available for bind-
ing to VIRIP. Indeed, attempts have 
been made to inhibit the HIV-1 gp41 
fusion process after insertion of the 
fusion peptide into the membrane 
by designing membrane-anchored 
fusion peptide analogs (Gerber et al., 
2004). Exposing the sticky finger prior 
to triggering would have deleterious 
consequences for gp120-gp41 (such 
as aggregation). Because we do not 
have a high-resolution structure of 
the gp120-gp41 trimer we can only 
speculate about the disposition of 
the fusion peptide in the overall struc-
ture. One speculation is that after the 
gp120 interaction with CD4 and core-
ceptors the fusion peptide spends 
some time between the viral and 
cell membranes disrupting the water 
structure and the respective repulsive 
hydration forces, and this leads to 
spontaneous local fusion (Dimitrov, 
1996). Further studies addressing the vier Inc.timing and location of VIRIP action 
may not only uncover new features of 
how it inhibits HIV entry but may also 
shed light on the elusive role of the 
fusion peptide itself.
Among the many implications of 
this study perhaps the most impor-
tant and urgent question, especially 
for individuals carrying HIV-1 isolates 
resistant to other drugs, is whether 
VIRIP variants, such as VIR-576, have 
therapeutic potential. Although only 
clinical trials could definitely answer 
this question, one could speculate 
that such a possibility exists, with T20 
providing an example of success. 
The unique mechanism of inhibition 
by VIRIP combined with a hopefully 
low level of resistant mutants holds 
promise for the use of this inhibitor in 
combination with other drugs. VIRIP 
and its variants are also the first HIV-1 
fusion inhibitors identified by the sys-
tematic screening of naturally occur-
ring mixtures of very high complexity. 
Even if the discovery of VIRIP does 
not lead to a new HIV-1 therapeutic, 
the methodology will undoubtedly 
have a profound impact on future 
research. Although labor intensive, 
the ability to screen human blood 
plasma and select peptides with pre-
defined properties promises to yield 
new compounds of importance for 
other diseases. Finally, these results 
suggest yet another possible mecha-
nism of resistance to HIV infection—
the induction of large amounts of 
inhibitory peptides during inflamma-
tion. How significant this mechanism 
might be in delaying the progression 
of HIV disease is an intriguing ques-
tion that remains to be answered.
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brain can consciously hold onto 
thoughts. This cognitive function, 
which is referred to as working mem-
ory, allows us to respond efficiently to 
the varying environmental demands 
of everyday life (Baddeley, 1986). 
Consider, for example, a waiter who 
takes your order at a restaurant with-
out using a notepad. To relay your 
order to the cook, he must maintain 
in working memory all the dishes you 
wanted plus any special requests. 
This information is short-lived—it may 
be erased once the food is brought 
to your table—but in the meantime it 
should be resistant to distractions, 
such as conversations with other 
people on the way to the kitchen. 
Although this is a complex cognitive 
function, a large body of experimental 
work has shown that neural circuits in 
the brain’s prefrontal cortex mediate 
working memory.
In this issue of Cell, Wang et al. 
(2007) report in several mammalian 
models the results of an experimental 
tour de force aimed at understand-
ing some of the key molecular proc-
esses that regulate neural circuits 
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of the prefrontal cortex during tasks 
that require spatial working memory. 
They discovered that the mental rep-
resentation of a spatial location held 
in working memory depends on the 
interaction between the postsynaptic 
α2A-adrenoceptors (α2A-ARs) and a 
class of ion channels called hyperpo-
larization-activated cyclic nucleotide 
channels (HCNs), which are gated by 
cAMP. This is a remarkable advance, 
not only because they tease out the 
functional interaction between these 
molecules and their effect on working 
memory, but also because the results 
provide a rational basis for the devel-
opment of clinical therapies to treat 
mental disorders involving the pre-
frontal cortex.
Funahashi et al. (1989) originally 
showed that, in monkeys perform-
ing a task involving spatial working 
memory, neurons in the prefrontal 
cortex respond selectively to memo-
rized locations. In this now classic 
task, a small visual cue is briefly pre-
sented along a circle, and monkeys 
have to remember its position for 
few seconds during what is called 
the delay period; the position of the 
emember
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cue changes from trial to trial. Indi-
vidual cells in the prefrontal cortex 
are selectively active during the delay 
period, such that some neurons fire 
action potentials at a high rate only 
when the position being remembered 
is at or near a specific preferred direc-
tion. This preferred direction varies 
from cell to cell. In this way, specific 
populations of neurons maintain a 
representation of the location of any 
stimulus presented in the visual field. 
It was later shown that sustaining this 
activity depends on strong connec-
tions within these networks (Compte 
et al., 2000). In essence, neurons with 
similar spatial preferences tend to 
excite each other, whereas neurons 
with dissimilar spatial preferences 
tend to inhibit each other, such that 
only a few neurons remain strongly 
active during the delay period.
Neurons in the prefrontal cortex are 
modulated by inputs from the nore-
pinephrine system, which projects to 
the prefrontal cortex from the brain 
stem. The influence of norepine-
phrine is mediated via postsynaptic 
α2A-ARs, and manipulation of these 
receptors can strongly affect work-
e, Winston-Salem, NC 27157-1010 USA
xico, D.F., México
ormation in the brain. In this 
f molecular events involving 
cAMP tune the responses of 
